Conclusions
The current study demonstrated that the recombinant humanized anti-VEGF monoclonal antibody injection was bioequivalent to Avastin®. The safety and immunogenicity were similar between the two groups. Subsequent studies should investigate recombinant humanized anti-VEGF monoclonal antibody injection in patients setting.